Neurogene (NGNE) Cash from Investing Activities (2013 - 2026)
Neurogene's (NGNE) quarterly Cash from Investing Activities came in at $46.2 million in Q1 2026, up 202.65% YoY from $15.3 million in Q1 2025, and up 56.17% on a QoQ basis from $29.6 million in Q4 2025.
Neurogene (NGNE) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Cash from Investing Activities data on file, last reported at $46.2 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 202.65% year-over-year to $46.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.3 million (up 152.58% YoY) and the FY2025 annual result came in at $14.0 million, up 111.18% from the prior year.
- Cash from Investing Activities climbed to $46.2 million in Q1 2026, from $29.6 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $65.4 million in Q4 2022 to a low of -$102.6 million in Q4 2024.
- A 5-year average of -$2.4 million and a median of -$82000.0 in 2023 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 103324.14% in 2024, down 35224.39% in 2024.
- Tracing NGNE's Cash from Investing Activities over 5 years: stood at $65.4 million in 2022, then plunged by 60.49% to $25.8 million in 2023, then sank by 497.27% to -$102.6 million in 2024, then surged by 128.85% to $29.6 million in 2025, then soared by 56.17% to $46.2 million in 2026.
- The last three Cash from Investing Activities figures came in at $46.2 million (Q1 2026), $29.6 million (Q4 2025), and $22.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 6.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.10 Mn |
| Jun 30, 2026 | 6.10 Mn |
| Mar 31, 2026 | 46.24 Mn |
| Mar 31, 2026 | 46.24 Mn |
| Dec 31, 2025 | 29.61 Mn |
| Dec 31, 2025 | 29.61 Mn |
| Sep 30, 2025 | 21.99 Mn |
| Sep 30, 2025 | 21.99 Mn |
| Jun 30, 2025 | 7.45 Mn |
| Jun 30, 2025 | 7.45 Mn |
| Mar 31, 2025 | -45.05 Mn |
| Mar 31, 2025 | -45.05 Mn |
| Dec 31, 2024 | -102.62 Mn |
| Dec 31, 2024 | -102.62 Mn |
| Sep 30, 2024 | -28.97 Mn |
| Sep 30, 2024 | -28.97 Mn |
| Jun 30, 2024 | -23.61 Mn |
| Jun 30, 2024 | -23.61 Mn |
| Mar 31, 2024 | 29.94 Mn |
| Mar 31, 2024 | 29.94 Mn |